In February 2017, the Belgian drug discovery Confo Therapeutics, a spin-off from Vrije Universiteit Brussel and VIB, announced that it received two grants bringing in a total of € 2.6 million over a period of two years.
VLAIO (Flanders Innovation and Entrepreneurship) and Innoviris Brussels awarded the grants to support the discovery of a fibrosis treatment and to expand the applicability of their proprietary Confo® technology. With nearly 45% of all deaths in the developed world, chronic inflammatory and fibrogenic disorders represent a major challenge for today’s medicine. Fibrosis is therefore an important research area for therapeutic drug development.
About Confo Therapeutics
Confo Therapeutics is a drug discovery company built around a disruptive technology, which enables it to address ‘undruggable’ GPCRs. The company is building a portfolio of transformative medicines in various disease areas. Confo Therapeutics is located in Brussels and has recently expanded to a second exploitation site on the technology park in Zwijnaarde/Ghent.
Want to become part of this promising biotech company?
We are delighted to highlight our collaboration with Confo Therapeutics. We are currently looking for a scientist in structural biology, and a research associate in early drug discovery.
Confo Therapeutics is looking for a highly motivated and skilled (Senior) Scientist – Structural Biology to strengthen their Drug Discovery team.
Confo Therapeutics is looking for a highly motivated and skilled Research Associate – Early Drug Discovery to expand their Target Discovery team.